Advertisement

High-Grade Gliomas

  • Gregory Vlacich
  • Christina I. Tsien
Chapter

Abstract

High-grade gliomas constitute one of the more widely studied and persistently challenging primary malignancies of the central nervous system. Historically identified by their clinical and histologic appearance, advancements in molecular genetics including the identification of MGMT and IDH1/2 have led to significant changes in how these tumors are classified and our ability to predict treatment response and survival as well as guide treatment. Despite this, the general treatment paradigm of surgery followed by adjuvant chemotherapy and radiation remains the standard of care with only modest advances in the overall prognosis of this disease. Long-term survival, particularly with glioblastoma multiforme, is rare, and treatment of recurrent disease is effectively palliative in nature. Nevertheless, as we expand our knowledge of the molecular basis of this disease, additional insight into prognosis and options for personalized therapies continue to offer the potential for improved outcomes.

Keywords

Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma MGMT IDH Radiation therapy Temozolomide Bevacizumab 

References

  1. 1.
    Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492.CrossRefPubMedGoogle Scholar
  2. 2.
    Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group. Lyon, France: IARS Press; 2007.Google Scholar
  3. 3.
    Ostrum QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1.CrossRefGoogle Scholar
  4. 4.
    Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer. 2011;11:325.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell. 2002;1:125.CrossRefPubMedGoogle Scholar
  6. 6.
    Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557.CrossRefPubMedGoogle Scholar
  7. 7.
    Hansen EK, Roach M, editors. Handbook of evidence-based radiation oncology. 2nd ed. New York, NY: Springer Science + Business Media; 2010.Google Scholar
  8. 8.
    Ironside JW, Moss TH, Louis DN, et al. Diagnostic pathology of the nervous system tumours. London: Churchill Livingstone; 2002.Google Scholar
  9. 9.
    Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011.CrossRefPubMedGoogle Scholar
  10. 10.
    Marko NF, Weil RJ, Schroeder JL, et al. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32:774.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hegi ME, Diserens AC, Gorila T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997.CrossRefPubMedGoogle Scholar
  12. 12.
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987.CrossRefPubMedGoogle Scholar
  13. 13.
    Gerstner ER, Yip S, Wang DL, et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009;73:1509.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011;12:83.CrossRefPubMedGoogle Scholar
  15. 15.
    Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337.CrossRefPubMedGoogle Scholar
  16. 16.
    van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344.CrossRefPubMedGoogle Scholar
  17. 17.
    Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803.CrossRefGoogle Scholar
  18. 18.
    Reuss DE, Kratz A, Sahm F, et al. Adult IDH wildtype astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130:407.CrossRefPubMedGoogle Scholar
  19. 19.
    Paleologos TS, Dorward NL, Wadley JP, et al. Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases. Neurosurgery. 2001;49:830.PubMedGoogle Scholar
  20. 20.
    Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293.PubMedGoogle Scholar
  21. 21.
    McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97:794.CrossRefPubMedGoogle Scholar
  22. 22.
    Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467.CrossRefPubMedGoogle Scholar
  23. 23.
    Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190.CrossRefPubMedGoogle Scholar
  24. 24.
    Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238.CrossRefPubMedGoogle Scholar
  25. 25.
    Krishnan R, Raabe A, Hattingen E, et al. Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome. Neurosurgery. 2004;55:904.CrossRefPubMedGoogle Scholar
  26. 26.
    Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc. 2001;76:677.CrossRefPubMedGoogle Scholar
  27. 27.
    Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med. 2008;358:18.CrossRefPubMedGoogle Scholar
  28. 28.
    Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-animolevulinic acid for resection of malignant glioma: a randomized controlled multicenter phase III trial. Lancet Oncol. 2006;7:392–401.CrossRefPubMedGoogle Scholar
  29. 29.
    Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323.CrossRefPubMedGoogle Scholar
  30. 30.
    Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol. 1978;17:475.CrossRefPubMedGoogle Scholar
  31. 31.
    Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery. 1988;22:465.CrossRefPubMedGoogle Scholar
  32. 32.
    Chan JL, Lee SW, Sandler HM, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635.CrossRefPubMedGoogle Scholar
  33. 33.
    Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res. 2012;18:273.CrossRefPubMedGoogle Scholar
  34. 34.
    Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459.CrossRefGoogle Scholar
  35. 35.
    Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma. J Clin Oncol. 2011;15(Suppl):141s.Google Scholar
  36. 36.
    Quinn JA, Jiang SX, Rearden DA, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Quinn JA, Jiang SX, Carter J, et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009;15:1064.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142.CrossRefPubMedGoogle Scholar
  39. 39.
    Chang S, Zhang P, Cairncross JG, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG oncology RTOG 9813. Neuro Oncol. 2016;19:252.PubMedCentralGoogle Scholar
  40. 40.
    Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    van den Bent M, Erridge S, Vogelbaum MA, et al. Results of the interim analysis of the EORTC randomized phase III CANTON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: an intergroup trial. J Clin Oncol. 2016;34(Suppl):abstr LBA2000.Google Scholar
  42. 42.
    van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715.CrossRefPubMedGoogle Scholar
  43. 43.
    Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodedrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28:4601.CrossRefPubMedGoogle Scholar
  45. 45.
    Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583.CrossRefPubMedGoogle Scholar
  46. 46.
    Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33:4145.CrossRefPubMedGoogle Scholar
  47. 47.
    Wick W, Platten M, Mesiner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707.CrossRefPubMedGoogle Scholar
  48. 48.
    Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027.CrossRefPubMedGoogle Scholar
  49. 49.
    Halperin EC, Bentel G, Heinz ER, et al. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post morten topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys. 1989;17:1347–50.CrossRefPubMedGoogle Scholar
  50. 50.
    Parsons JT, Bova FJ, Fitzgerald CR, et al. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys. 1994;30:775.CrossRefPubMedGoogle Scholar
  51. 51.
    Nwokedi EC, DiBiase SJ, Jabbour S, et al. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery. 2002;50:41.PubMedGoogle Scholar
  52. 52.
    Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853.CrossRefPubMedGoogle Scholar
  53. 53.
    Minniti G, Armosini V, Salvati M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol. 2001;103:683.CrossRefGoogle Scholar
  54. 54.
    Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291.CrossRefPubMedGoogle Scholar
  55. 55.
    Combs SE, Widmer V, Thilmann C, et al. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005;104:2168.CrossRefPubMedGoogle Scholar
  56. 56.
    Hall WA, Djalilian HR, Lamborn KR, et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol. 1995;13:1642.CrossRefPubMedGoogle Scholar
  57. 57.
    Laing RW, Warrington AP, Graham J, et al. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). Radiother Oncol. 1993;27:22.CrossRefPubMedGoogle Scholar
  58. 58.
    Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47.CrossRefPubMedGoogle Scholar
  59. 59.
    Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1996;35:37.CrossRefPubMedGoogle Scholar
  60. 60.
    Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51:343.CrossRefPubMedGoogle Scholar
  61. 61.
    Wilson CB, Larson DA, Gutin PH. Radiosurgery: a new application? J Clin Oncol. 1992;10:1373.CrossRefPubMedGoogle Scholar
  62. 62.
    Ten Haken RK, Thornton AF Jr, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol. 1992;25:121.CrossRefPubMedGoogle Scholar
  63. 63.
    Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64:892.CrossRefPubMedGoogle Scholar
  64. 64.
    Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84:967.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol. 1991;12:45.PubMedGoogle Scholar
  66. 66.
    Galban CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009;15:572.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from psuedoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Verma N, Cowperthwaite MC, Burnett MG, et al. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013;15:515.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733.CrossRefPubMedGoogle Scholar
  70. 70.
    Wick W, Brandes AA, Gorlia T, et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of glioblastoma. J Clin Oncol. 2016;34(Suppl):abstr 2001.CrossRefGoogle Scholar
  71. 71.
    Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomistine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Perry JR, Belanger K, Mason WP, et al. Phase II continuous dose-dense temozolmide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2051;2010:28.Google Scholar
  74. 74.
    Weller M, Tabatabai G, Kastner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21:2057.CrossRefPubMedGoogle Scholar
  75. 75.
    Hudes RS, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:293.CrossRefPubMedGoogle Scholar
  76. 76.
    Kim HK, Thornton AF, Greenberg HS, et al. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am J Clin Oncol. 1997;20:358.CrossRefPubMedGoogle Scholar
  77. 77.
    Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000;23:155.CrossRefPubMedGoogle Scholar
  78. 78.
    Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863.CrossRefPubMedGoogle Scholar
  79. 79.
    Nieder C, Astner ST, Mehta MP, et al. Improvement, clinical course and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol. 2008;31:300.CrossRefPubMedGoogle Scholar
  80. 80.
    Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28:3048.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Mayer R, Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys. 2008;70:1350.CrossRefPubMedGoogle Scholar
  82. 82.
    Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453–61.CrossRefPubMedGoogle Scholar
  84. 84.
    Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefPubMedGoogle Scholar
  85. 85.
    Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–22.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma Science. 2011;333(6048):1453–5.Google Scholar
  87. 87.
    Van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011;17(22):7148–55.CrossRefPubMedGoogle Scholar
  88. 88.
    Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33(7):1349–55.CrossRefPubMedGoogle Scholar
  89. 89.
    Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations